MTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 493-504

  Giovannini, Marco ^a,b   Bonne, Nicolas Xavier ^a   Vitte, Jeremie ^a   Chareyre, Fabrice ^a   Tanaka, Karo ^a   Adams, Rocky ^a   Fisher, Laurel M ^a   Valeyrie Allanore, Laurence ^c   Wolkenstein, Pierre ^c   Goutagny, Stephane ^d,g   Kalamarides, Michel ^e,f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d BEAUJON HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g Université Paris 13   (France)

Author keywords

Neurofibromatosis type 2; Rapamycin; Schwannoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MERLIN; RAPAMYCIN;

ACOUSTIC NEURINOMA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 2; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RARE DISEASE; SCHWANN CELL; TUMOR GROWTH; TUMOR VOLUME;

NEUROFIBROMATOSIS TYPE 2; RAPAMYCIN; SCHWANNOMA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SIZE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84896987758     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not242     Document Type: Article

References (47)

1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1-v49.
2. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.
3. Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012;158A:24-41.
4. Hadfield KD, Smith MJ, Urquhart JE, et al.Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene. 2010;29:6216-6221.
5. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 1997;151:1649-1654.
6. McClatchey AI, Fehon RG. Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 2009;19:198-206.
7. Li W, Cooper J, Karajannis MA, et al. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep. 2012;13: 204-215.
8. James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29:4250-4261.
9. Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of thetumorsuppressor gene NF2, encoding merlin, constitutively activates integrindependent mTORC1 signaling. Mol Cell Biol. 2009;29:4235-4249.
10. Wong M. mTOR as a potential treatment target for epilepsy. Future Neurol. 2012;7:537-545.
11. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472-1487.
12. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Human Mol Genet. 2005; 14(Spec No. 2):R251-R258.
13. Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther. 2011;11:1181-1192.
14. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125-132.
15. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growthmachinery. Cell. 2002;110:163-175.
16. Yip CK, Murata K,Walz T, et al. Structure of the humanmTOR complex I and its implications for rapamycin inhibition.MolCell. 2010;38:768-774.
17. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170.
18. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibitsmTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168.
19. Laplante M, Sabatini DM.mTORsignaling in growth control and disease. Cell. 2012;149:274-293.
20. James MF, Stivison E, BeauchampR, et al. Regulation ofmTORcomplex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res. 2012;10:649-659.
21. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 1999;13:978-986.
22. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage. 2006;31:1116-1128.
23. Bashour AM, Meng JJ, Ip W, et al. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells. Mol Cell Biol. 2002;22:1150-1157.
24. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene. 1998;17:2195-2209.
25. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 2004;64:3718-3724.
26. Tanaka K, Eskin A, Chareyre F, et al. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res. 2013;19: 3856-3870.
27. Lee N, Woodrum CL, Nobil AM, et al. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009;9:8.
28. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508.
29. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103:1475-1479.
30. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005;4:101-112.
31. Nakamura H, Jokura H, Takahashi K, et al. Serial follow-up MR imaging after gamma knife radiosurgery for vestibular schwannoma. Am J Neuroradiol. 2000;21:1540-1546.
32. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759.
33. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev. 2005; 19:2265-2277.
34. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327-332.
35. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15:5032-5039.
36. Evans GR, Lloyd SK, Ramsden RT. Neurofibromatosis type 2. Adv Otorhinolaryngol. 2011;70:91-98.
37. Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res. 2013;19: 1180-1189.
38. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005;11:4074-4082.
39. Peyre M, Goutagny S, Bah A, et al. Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery. 2013;72: 907-914.
40. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 0000;12:14-18.
41. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358-367.
42. Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg. 2012;117:109-117.
43. Goutagny S, Bah AB, Henin D, et al. Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol. 2012;14: 1090-1096.
44. Chen Z, Cheng K,Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012; 483:613-617.
45. Lunardi A, Ala U, Epping MT, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45:747-755.
46. Nardella C, Lunardi A, Patnaik A, et al. The APL paradigm and the "co-clinical trial" project. Cancer Disc. 2011;1:108-116.
47. Rosen N, She QB. AKTand cancer - is it all mTOR? Cancer Cell. 2006;10: 254-256.